- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04572906
Seguridad y eficacia de NTX-001 en comparación con SOC en lesiones nerviosas periféricas únicas agudas
Estudio de fase 2a, multicéntrico, aleatorizado, cegado por el paciente y el evaluador, controlado, que evalúa la seguridad y la eficacia de NTX-001 en comparación con el SOC en el tratamiento de la lesión aguda de un nervio periférico seccionado que se produce por debajo del borde distal del plexo braquial y requiere reparación quirúrgica.
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 16 and 80 years of age.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
NTX-001 (Product) is a surgical product that consists of an active solution (drug), an isolation chamber medical device (chamber or device) and two (2) other sterile solutions.
NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32607
- UF Health - University of FL - Gainesville
-
Orlando, Florida, Estados Unidos, 32806
- Orlando Health
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- Indiana Hand to Shoulder Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, Estados Unidos, 21218
- Curtis National Hand Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43202
- The Ohio State University Wexner Medical Center Hand and Upper Extremity Center
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23398
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98107
- Harborview Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- The subject is at least 12 years of age and not older than 80.
- The subject has sustained a confirmed (intra-op assessment) single transected peripheral nerve injury.
- The subject's nerve injury is classified as Sunderland's Fourth and Fifth Degree (Class III)
- The subject's nerve injury is amenable to minimal or acceptable tension, in direct, end-to-end repair.
- The surgical repair will occur within 48 hours of injury.
Exclusion Criteria:
- The subject has a PNI with a segmental loss (gap) that cannot be repaired with minimal or acceptable tension.
- Other treatments known to affect the growth and/or physiology of the neural and vascular system.
- The nerve injury has vascular damage that cannot be repaired to provide adequate perfusion of the injured site.
- The subject is pregnant and/or is breastfeeding.
- The subject has a significant medical comorbidity precluding immediate repair.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: NTX-001
NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy. |
One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
Otros nombres:
|
|
Sin intervención: Standard of Care
standard suture neurorrhaphy |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline Michigan Hand Questionnaire Total Score (MHQ)
Periodo de tiempo: Baseline and Week 12
|
The MHQ measures hand function and is scored from 0-100; with 100 being the "best" score. |
Baseline and Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Responder Analysis for % Recovery of MHQ Total Score > Than or = to 75% Cutoff
Periodo de tiempo: Baseline, Weeks 8, 12, 24, 48
|
The MHQ measures hand function and is scored from 0-100; with 100 being the "best" score. |
Baseline, Weeks 8, 12, 24, 48
|
|
Change From Baseline Numeric Pain Rating Scale (NPRS)
Periodo de tiempo: Baseline and at Weeks 4, 8, 12, 24, 36 and 48
|
The NPRS measures pain intensity on a scale from 0 representing no pain and 10 to the worst pain as bad as you can imagine. |
Baseline and at Weeks 4, 8, 12, 24, 36 and 48
|
|
Number of Responders to Modified British Medical Research Council (MMRC) Sensory Grading (S0-S4)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24, 36 and 48
|
The MMRC sensory grading scale was used to assess sensory recovery based on pain/touch sensibility and static and moving two-point discrimination testing (STPD and MTPD). The scale ranges from S0 to S4, where S0 = no sensory recovery; S1 = recovery of deep cutaneous pain sensibility; S2 = recovery of some superficial pain and tactile sensibility; S3 = recovery of pain and tactile sensibility with imperfect localization and two-point discrimination; and S4 = complete sensory recovery. Higher scores indicate better sensory recovery. A responder was defined as a participant achieving a sensory recovery grade of S3 or greater (S3+). Data presented are the percentage of participants who met the S3+ responder criterion at each assessment time point. |
Baseline, Weeks 4, 8, 12, 24, 36 and 48
|
|
Number of Responders to Modified British Medical Research Council (MMRC) Motor Grading (M0-M5)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24, 36 and 48
|
The MMRC motor grading scale was used to assess motor recovery. Motor function was evaluated on an ordinal scale ranging from M0 to M5, where M0 indicates no muscle contraction and M5 indicates normal muscle strength. Grades were defined as follows: M0 = no contraction; M1 = muscle contraction without joint movement; M2 = active movement with gravity eliminated; M3 = active movement against gravity; M4 = active movement against resistance; and M5 = normal muscle strength. Higher scores indicate better motor recovery. A responder was defined as a participant achieving a motor function score of M3 or greater (M3+). Data presented are the percentage of participants meeting the M3+ responder criterion at each assessment time point. |
Baseline, Weeks 4, 8, 12, 24, 36 and 48
|
|
Number of Responders to Semmes-Weinstein Monofilament Test (SWMT)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24, 36 and 48
|
The Semmes-Weinstein Monofilament Test (SWMT) was used to assess sensory function of the affected nerve. A responder was defined as a participant with a return to normal gauge sensation (2.83 g) for the affected nerve. Lower scores indicate better sensory function, with 2.83 g corresponding to normal sensation. Data presented are the percentage of participants who met the responder criterion at each assessment time point. |
Baseline, Weeks 4, 8, 12, 24, 36 and 48
|
|
Change From Baseline Cold Intolerance Symptom Severity (CISS)
Periodo de tiempo: Baseline and at Weeks 4, 8, 12, 24 and 48
|
The CISS focuses on the impact of cold intolerance on activities of daily life; the score ranges a score between 0 and 100, where 0 is no symptoms at all and 100 is the most severe symptoms you can possibly imagine. |
Baseline and at Weeks 4, 8, 12, 24 and 48
|
|
Number of Responders to Patient Global Impression of Change (PGIC)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24 and 48
|
The Patient Global Impression of Change (PGIC) is a patient-reported assessment of overall change in health status since treatment initiation. Participants rate their condition on a 7-point scale: 1 = very much worse, 2 = much worse, 3 = minimally worse, 4 = no change, 5 = minimally improved, 6 = much improved, and 7 = very much improved. Higher scores indicate greater perceived improvement. A responder was defined as a participant with a PGIC score of 5 or greater. Data presented are the percentage of participants who met the responder criterion at each assessment time point. |
Baseline, Weeks 4, 8, 12, 24 and 48
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Michigan Hand Questionnaire (MHQ) Activities of Daily Living
Periodo de tiempo: Baseline and at Weeks 8, 12, 24, 48
|
The MHQ Two Domain Score analyses consisted of the average of the domain Activities of Daily Living (ADL). MHQ Activities of Daily Living normalized score ranges from 0 to 100, with 0 being the worst score and 100 the best. |
Baseline and at Weeks 8, 12, 24, 48
|
|
Change From Baseline in MHQ Pain Score
Periodo de tiempo: Baseline and at Weeks 8, 12, 24, 48
|
The MHQ Two Domain Score analyses consisted of the average of the pain domain. MHQ Pain normalized score ranges from 0 to 100, with 0 being the best score and 100 the worst. |
Baseline and at Weeks 8, 12, 24, 48
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Seth Schulman, MD, Neuraptive Therapeutics Inc.
Publicaciones y enlaces útiles
Publicaciones Generales
- Ghergherehchi CL, Mikesh M, Sengelaub DR, Jackson DM, Smith T, Nguyen J, Shores JT, Bittner GD. Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion. J Neurosci Methods. 2019 Feb 15;314:1-12. doi: 10.1016/j.jneumeth.2018.12.015. Epub 2018 Dec 23.
- Mikesh M, Ghergherehchi CL, Louis Hastings R, Ali A, Rahesh S, Jagannath K, Sengelaub DR, Trevino RC, Jackson DM, Bittner GD. Corrigendum to "Polyethylene glycol solutions rapidly restore and maintain axonal continuity, neuromuscular structures, and behaviors lost after sciatic nerve transections in female rats.". J Neurosci Res. 2018 Sep;96(9):1623. doi: 10.1002/jnr.24277. No abstract available.
- Mikesh M, Ghergherehchi CL, Rahesh S, Jagannath K, Ali A, Sengelaub DR, Trevino RC, Jackson DM, Tucker HO, Bittner GD. Corrigendum to "Polyethylene glycol treated allografts not tissue matched nor immunosuppressed rapidly repair sciatic nerve gaps, maintain neuromuscular functions, and restore voluntary behaviors in female rats". J Neurosci Res. 2018 Sep;96(9):1624. doi: 10.1002/jnr.24278. No abstract available.
- Bittner GD, Spaeth CS, Poon AD, Burgess ZS, McGill CH. Repair of traumatic plasmalemmal damage to neurons and other eukaryotic cells. Neural Regen Res. 2016 Jul;11(7):1033-42. doi: 10.4103/1673-5374.187019.
- Bittner GD, Sengelaub DR, Trevino RC, Peduzzi JD, Mikesh M, Ghergherehchi CL, Schallert T, Thayer WP. The curious ability of polyethylene glycol fusion technologies to restore lost behaviors after nerve severance. J Neurosci Res. 2016 Mar;94(3):207-30. doi: 10.1002/jnr.23685. Epub 2015 Nov 3.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NTx20201
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .